S C Heslinga, T C Konings, I E van der Horst-Bruinsma, O Kamp, V P van Halm, Hacm de Bruin-Bon, M J Peters, M T Nurmohamed
{"title":"高利单抗治疗对强直性脊柱炎患者左室收缩和舒张功能的影响。","authors":"S C Heslinga, T C Konings, I E van der Horst-Bruinsma, O Kamp, V P van Halm, Hacm de Bruin-Bon, M J Peters, M T Nurmohamed","doi":"10.2147/BTT.S176806","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Diastolic left ventricular (LV) dysfunction appears more prevalent in ankylosing spondylitis (AS). The effects of tumor necrosis factor alpha (TNF-α) blocking therapy, a strong and effective anti-inflammatory drug, on diastolic LV function in AS are unknown. The objective of the study was to find the effects of 1-year treatment with golimumab 50 mg subcutaneously once per month on systolic and diastolic LV dysfunction in AS patients.</p><p><strong>Methods: </strong>Forty consecutive AS patients were treated with TNF-α blocking therapy for 1 year. Transthoracic echocardiography was performed in all patients at baseline and after 1 year of treatment.</p><p><strong>Results: </strong>Diastolic LV function improved after treatment in four out of six (67%) AS patients who completed follow-up (<i>P</i>=0.125), and did not develop or worsen in any of the other patients. Treatment with TNF-α blocking therapy had no effect on systolic LV function.</p><p><strong>Conclusion: </strong>These findings give support to the hypothesis that diastolic LV dysfunction improves during treatment with TNF-α blocking therapy.</p>","PeriodicalId":9025,"journal":{"name":"Biologics : Targets & Therapy","volume":"12 ","pages":"143-149"},"PeriodicalIF":5.3000,"publicationDate":"2018-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2147/BTT.S176806","citationCount":"2","resultStr":"{\"title\":\"The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis.\",\"authors\":\"S C Heslinga, T C Konings, I E van der Horst-Bruinsma, O Kamp, V P van Halm, Hacm de Bruin-Bon, M J Peters, M T Nurmohamed\",\"doi\":\"10.2147/BTT.S176806\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Diastolic left ventricular (LV) dysfunction appears more prevalent in ankylosing spondylitis (AS). The effects of tumor necrosis factor alpha (TNF-α) blocking therapy, a strong and effective anti-inflammatory drug, on diastolic LV function in AS are unknown. The objective of the study was to find the effects of 1-year treatment with golimumab 50 mg subcutaneously once per month on systolic and diastolic LV dysfunction in AS patients.</p><p><strong>Methods: </strong>Forty consecutive AS patients were treated with TNF-α blocking therapy for 1 year. Transthoracic echocardiography was performed in all patients at baseline and after 1 year of treatment.</p><p><strong>Results: </strong>Diastolic LV function improved after treatment in four out of six (67%) AS patients who completed follow-up (<i>P</i>=0.125), and did not develop or worsen in any of the other patients. Treatment with TNF-α blocking therapy had no effect on systolic LV function.</p><p><strong>Conclusion: </strong>These findings give support to the hypothesis that diastolic LV dysfunction improves during treatment with TNF-α blocking therapy.</p>\",\"PeriodicalId\":9025,\"journal\":{\"name\":\"Biologics : Targets & Therapy\",\"volume\":\"12 \",\"pages\":\"143-149\"},\"PeriodicalIF\":5.3000,\"publicationDate\":\"2018-11-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2147/BTT.S176806\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biologics : Targets & Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/BTT.S176806\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2018/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biologics : Targets & Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/BTT.S176806","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis.
Background: Diastolic left ventricular (LV) dysfunction appears more prevalent in ankylosing spondylitis (AS). The effects of tumor necrosis factor alpha (TNF-α) blocking therapy, a strong and effective anti-inflammatory drug, on diastolic LV function in AS are unknown. The objective of the study was to find the effects of 1-year treatment with golimumab 50 mg subcutaneously once per month on systolic and diastolic LV dysfunction in AS patients.
Methods: Forty consecutive AS patients were treated with TNF-α blocking therapy for 1 year. Transthoracic echocardiography was performed in all patients at baseline and after 1 year of treatment.
Results: Diastolic LV function improved after treatment in four out of six (67%) AS patients who completed follow-up (P=0.125), and did not develop or worsen in any of the other patients. Treatment with TNF-α blocking therapy had no effect on systolic LV function.
Conclusion: These findings give support to the hypothesis that diastolic LV dysfunction improves during treatment with TNF-α blocking therapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
